Etoricoxib Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a crystalline bipyridinyl methylsulfone active substance supplied as white to off-white powder under pharmacopoeial-grade release documentation. The molecular formula is C₁₈H₁₅ClN₂O₂S, the molecular weight is 358.84 g/mol, and the CAS registry number is 202409-33-4. The product model encompasses oral-grade and injectable-grade sub-classes; the injectable sub-class is typically micronized and controlled for bioburden, while the oral sub-class may be supplied as unmicronized or impact-milled material with particle-size ranges matched to direct compression, dry granulation, wet granulation, capsule filling, or granule production. The substance is practically insoluble in water and exhibits low-solubility/high-permeability behaviour consistent with BCS Class II; therefore particle-size distribution, polymorphic form, and dissolution control are release-critical parameters for every solid oral dosage form.

What differentiates the bipyridinyl methylsulfone scaffold from sulfonamide COX-2 inhibitors?

The structural identity of etoricoxib is 5-chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine. The central bipyridinyl unit and the terminal methylsulfone group distinguish it from celecoxib, which is a 1,5-diarylpyrazole containing a sulfonamide substituent, and from valdecoxib, which is an isoxazole sulfonamide. The absence of a sulfonamide moiety in etoricoxib is relevant to cross-reactivity assessment and alters solid-state crystal packing, because the methylsulfonyl group participates in different hydrogen-bonding motifs than the sulfonamide acceptor-donor pair. Published human pharmacokinetic data report a terminal elimination half-life of approximately 22 h, compared with roughly 11 h for celecoxib. Etoricoxib is cleared primarily by hepatic oxidation involving CYP3A4-mediated demethylation, whereas celecoxib is predominantly metabolized by CYP2C9. Plasma protein binding is reported as approximately 92%. These metabolic differences alter drug-interaction potential and require different active pharmaceutical ingredient control strategies; for example, residual solvent selection in the final crystallization must not introduce strong CYP3A4 inhibitors or inducers as impurities. In vitro whole-blood assays demonstrate higher COX-2 selectivity for etoricoxib than for traditional non-selective NSAIDs, but exact selectivity ratios vary with assay matrix, incubation time, and donor variability; published data for this specific configuration should be interpreted against the assay standard used. The structural consequence is that etoricoxib does not carry the sulfonamide moiety associated with some hypersensitivity syndromes; however, the absence of a sulfonamide group does not eliminate all immunological risk, and the API must be controlled for process-related residual solvents and protein-reactive impurities.

Rofecoxib is included for structural comparison only because its regulatory status differs from that of etoricoxib. The table summarizes publicly available pharmacokinetic and structural data; the values are not acceptance criteria for API release.

Pharmacopoeial release parameters and impurity control framework

The API is released using validated liquid chromatography methods that separate process-related impurities, degradation products, and residual synthesis intermediates. A typical release specification for the oral grade includes assay by HPLC on an anhydrous, solvent-free basis between 98.0% and 102.0% w/w, total impurities not more than 0.5% area normalization, and any unspecified impurity not more than 0.10% area normalization. Identification is confirmed by infrared absorption spectrophotometry against a reference standard, supported by retention-time agreement in the assay chromatogram. Water content is determined by Karl Fischer titration with an acceptance criterion commonly set at not more than 0.5% w/w to minimize hydrolytic degradation and powder-flow variability. Residual solvents are controlled under ICH Q3C(R8); methanol is normally limited to not more than 3000 ppm and dichloromethane to not more than 600 ppm when these solvents are identified in the manufacturing route. Elemental impurities are evaluated according to ICH Q3D Table 1 and comply with oral and parenteral permitted daily exposure limits; the injectable grade requires lower limits for cadmium, lead, arsenic, and mercury and may require additional trace-metal verification by inductively coupled plasma mass spectrometry.

Mutagenic impurities are assessed under ICH M7(R1) with a staged threshold approach; the API manufacturer is expected to document the absence of key starting material impurities and any nitroso derivatives via liquid chromatography–high-resolution mass spectrometry. Because etoricoxib is a non-sulfonamide methylsulfone compound, nitrosating species arising from residual nitrate or nitrite in excipients or process water are controlled along the synthesis and formulation. The API should be stored in tightly closed containers protected from light and moisture; elevated humidity above 60% RH requires desiccant protection to prevent surface hydration and particle agglomeration. The assigned retest interval is determined under ICH Q1A(R2) stability protocols and is commonly 24–36 months for the oral grade when stored at 25 °C/60% RH or 30 °C/65% RH, depending on the regulatory climate zone.

When particle size controls dissolution and blend homogeneity

For etoricoxib solid oral dosage forms, the dissolution rate is frequently the rate-limiting step for absorption because the compound is practically insoluble. Laser diffraction particle-size analysis under ISO 13320-1:2020 is therefore used to control volume-weighted D10, D50, and D90. For wet granulation and capsule filler operation, a D90 acceptance band of 75 μm to 150 μm is often sufficient, whereas direct compression and dry granulation may require a D90 below 100 μm to achieve acceptable content uniformity in low-dose strengths. Micronized injectable-grade material is typically controlled to a D90 of 10 μm to 20 μm and may be further processed by jet milling to reduce agglomeration. The specific acceptance range is not universal; it is set by the formulation scientist after a risk assessment addressing segregation, punch sticking, dissolution failure, and blend content uniformity across production-scale equipment.

Micronization increases specific surface area and reduces the diffusion boundary layer, but it can also generate electrostatic charge and increase moisture uptake. For this reason, particle-size reduction is coupled with X-ray powder diffraction per Ph. Eur. 2.9.33 to confirm that the designated non-solvated polymorph is retained. If partial amorphization is observed after jet milling, the material may require conditioning or blending with a less cohesive grade to avoid reduced physical stability. The processing boundary is defined by the onset of polymorphic transformation and by the increase in cohesive arching; published data for this specific configuration is limited, so production trials with a defined micronizer feed rate and grinding-gas pressure are used to establish the final specification.

Dissolution testing for etoricoxib immediate-release tablets is routinely performed using USP Apparatus II (paddle) at 75 rpm in 900 mL of 0.1 M hydrochloric acid or pH 6.8 phosphate buffer with 0.5% w/v sodium lauryl sulfate. The surfactant concentration is justified by the need to maintain sink conditions for a practically insoluble drug. Release acceptance criteria are generally set at not less than 80% dissolved in 30 min for immediate-release dosage forms; however, the exact criterion is product-specific and is established from pivotal biobatches.

For high-shear wet granulation, etoricoxib is commonly blended with lactose monohydrate or dibasic calcium phosphate anhydrous as filler, microcrystalline cellulose as dry binder, croscarmellose sodium or sodium starch glycolate as disintegrant, and magnesium stearate as lubricant. The product is compatible with aqueous granulating fluids only when the drying step is controlled below the polymorph conversion temperature and the residual moisture at the end of drying is returned to below 0.5% w/w. Fluid-bed drying with inlet air at 50 °C to 70 °C and a dew-point specification for the entering air reduces batch-to-batch variation in tablet hardness and in vitro dissolution. Roller compaction may be used as an alternative dry granulation route; the ribbon density should be monitored because overcompaction can shift the particle-size distribution of the milled granulate toward coarse fractions that segregate in tablet press feed frames. For capsule filling, the API is generally dispersed as a preblend or granulate; dosator and tamping-pin machines require controlled bulk density and flow function coefficient unless a force-feeder is used. A pronounced density difference between the API and the filler leads to charge-based segregation in the hopper and variable dose weights, so excipient selection should match the API's tapped density or use a wet granulate to lock the drug-to-excipient ratio.

Injectable processing requires solubility enhancement and terminal sterilization boundaries

The injectable-grade etoricoxib API is intended for sterile aqueous or non-aqueous presentations; however, the aqueous solubility at neutral pH is below the pharmaceutical definition of practically insoluble, so formulation development requires a solubility-enhancing carrier. Sulfobutylether-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, or polyethylene glycol-based cosolvent systems are typically evaluated; the choice depends on the target dose, route of administration, and the osmolality ceiling for the finished injection. The API itself is not sterile when supplied; the injectable grade is controlled for bioburden and endotoxin load to support subsequent sterile filtration or aseptic filling. Terminal sterilization by moist heat is limited by the degradation profile: etoricoxib undergoes hydrolytic and oxidative degradation at elevated temperature and pH, so steam sterilization is evaluated only when the formulation buffer and pH are selected to maintain assay and related substances within specification. Aseptic filtration of a nanofiltered solution through a 0.22 μm filter is the preferred manufacturing route when the drug is fully dissolved and the carrier system does not clog the membrane.

Stability of injectable solutions is highly pH-dependent; formulation development should bracket pH 4.0 to 8.0 and monitor appearance, sub-visible particles, assay, related substances, and cyclodextrin-related impurities. Sub-visible particle counts are evaluated under USP <788> or Ph. Eur. 2.9.19, and bacterial endotoxins are tested by Limulus amebocyte lysate assay per Ph. Eur. 2.6.14. The terminal half-life of etoricoxib permits once-daily oral dosing, but injectable administration requires a different benefit-risk assessment because the formulation excipients can influence local tolerability. The injectable grade is typically double-bagged and shipped in compatible polyethylene liners, with a bioburden limit aligned with Ph. Eur. 5.1.4 for non-sterile APIs intended for aseptic processing.

Running direct compression on rotary tablet presses and capsule fillers

Direct compression of etoricoxib is feasible for low-dose strengths when the API is preblended with a highly flowable filler system and the particle-size distribution is tight enough to prevent segregation. The formulation is typically subjected to mixing studies using a bin blender or V-blender at fill volumes between 40% and 70%; blend samples are withdrawn at predefined locations and times to test content uniformity under USP <905> and Ph. Eur. 2.9.6. Tablet compression is performed on rotary tablet presses with compression force, precompression force, and turret speed logged. Acceptable immediate-release tablets generally display hardness values between 50 N and 120 N, friability below 1.0% per USP <1216>, and disintegration times below 15 min for uncoated tablets. If magnesium stearate is used above 1.0% w/w or blended for longer than 5 min, the dissolution rate may decrease because the hydrophobic lubricant coats the API surface; this is a defined operational boundary for dry-blend formulations.

The formulation should be evaluated for stability under open-bottle conditions because etoricoxib is sensitive to photolytic degradation; amber glass or high-density polyethylene bottles with desiccant are typical packaging configurations. The API is packaged in double low-density polyethylene liners inside a high-density polyethylene drum or fibreboard drum. The outer package is labelled with the product name, batch number, expiration or retest date, and storage conditions. A desiccant sachet is included when the shipment will be stored in climate zone IV conditions or when the receiving warehouse is not humidity-controlled. The product should be quarantined in a secure, temperature-monitored warehouse at 15 °C to 25 °C before release, and any opened container should be immediately reclosed and desiccated. The API is not to be handled without engineering controls such as local exhaust ventilation and powder-containment measures, because the active substance has occupational exposure limits that must be defined by the downstream manufacturer's health and safety assessment under local chemical-control legislation.